上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2022 , Vol. 42 >Issue 7: 858 - 865

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.07.003

论著 · 基础研究

SMAD7在多发性骨髓瘤中的表达及对细胞增殖和耐药的影响

  • 丁贺 ,
  • 曹杨琳 ,
  • 何杨 ,
  • 魏星 ,
  • 杨剑峰
展开
  • 1.苏州大学苏州医学院唐仲英医学研究院血液学研究中心，苏州 215123
    2.苏州大学附属第一医院江苏省血液研究所，苏州 215006
    3.苏州大学附属第一医院消化内科，苏州 215006
丁　贺（1997—），女，硕士生；电子信箱：1838872960@qq.com。
杨剑峰，电子信箱：yangjianfeng@suda.edu.cn。

收稿日期: 2022-03-07

  录用日期: 2022-06-24

  网络出版日期: 2022-09-04

基金资助

国家自然科学基金(81673096)

收起

SMAD7 expression in multiple myeloma and its effect on cell proliferation and drug resistance

  • He DING ,
  • Yanglin CAO ,
  • Yang HE ,
  • Xing WEI ,
  • Jianfeng YANG
Expand
  • 1.Hematology Center, Cyrus Tang Medical Institute, Suzhou Medical College of Soochow University, Suzhou 215123, China
    2.The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, China
    3.Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
YANG Jianfeng, E-mail: yangjianfeng@suda.edu.cn.

Received date: 2022-03-07

  Accepted date: 2022-06-24

  Online published: 2022-09-04

Supported by

National Natural Science Foundation of China(81673096)

Fold

摘要

目的·分析Sma和Mad相关蛋白7（Sma- and Mad-related protein 7，SMAD7）在多发性骨髓瘤（multiple myeloma，MM）中的表达，以及其对MM细胞的增殖和耐药的影响。方法·获取基因表达综合（gene expression omnibus，GEO） 数据库中的3个数据集，分析SMAD7在健康捐献者和MM患者中的差异表达。通过收集8例健康捐献者和20例MM患者的骨髓标本，采用实时荧光定量PCR（quantitative real-time PCR，qPCR）检测骨髓CD138+ 细胞中SMAD7 mRNA的相对表达，并分析其与患者临床资料的关系。在MM细胞KMS11中过表达SMAD7后，通过CCK8实验、细胞周期实验观察SMAD7对MM细胞增殖的影响。采用不同浓度的硼替佐米处理过表达SMAD7的KMS11细胞后，观察SMAD7对MM细胞的耐药影响及细胞的凋亡情况。结果·数据集中SMAD7表达数据的分析显示，与健康捐献者相比，SMAD7 在MM患者中表达较高（均P<0.05）。qPCR检测结果显示，SMAD7 mRNA相对表达水平在MM患者中有上调（P=0.002），但未显示出与临床资料间存在关联。与对照细胞相比，过表达SMAD7后，KMS11的细胞活力均较高（均P<0.05）；且细胞周期分布亦发生了变化，S期细胞的比例有所下降（P=0.016）、G2/M期细胞的比例有所上升（P=0.005）；而经硼替佐米处理后，过表达SMAD7细胞的药物敏感性及凋亡水平均较低。结论·SMAD7在MM中表达上调，过表达SMAD7可促进MM细胞的增殖和耐药能力。

关键词： Sma和Mad相关蛋白7; 多发性骨髓瘤; 细胞增殖; 硼替佐米

本文引用格式

丁贺 , 曹杨琳 , 何杨 , 魏星 , 杨剑峰 . SMAD7在多发性骨髓瘤中的表达及对细胞增殖和耐药的影响[J]. 上海交通大学学报（医学版）, 2022 , 42(7) : 858 -865 . DOI: 10.3969/j.issn.1674-8115.2022.07.003

Abstract

Objective

·To analyze the expression of Sma- and Mad-related protein 7 (SMAD7) in multiple myeloma (MM), and its effect on the proliferation and drug resistance of MM cells.

Methods

·Three datasets from the Gene Expression Omnibus (GEO) database were obtained to analyze the differential expression of SMAD7 in healthy donors and MM. Bone marrow samples from 8 healthy donors and 20 MM patients were collected. The relative expression of SMAD7 mRNA in bone marrow CD138+ cells was detected by quantitative real-time PCR (qPCR), and the relationship between SMAD7 mRNA expression and clinical information of patients was analyzed. After overexpression of SMAD7 in MM cells KMS11, the effects of SMAD7 on the proliferation was observed by CCK8 assay and cell cycle assay. KMS11 cells overexpressing SMAD7 were treated with different concentrations of bortezomib, and the effect of SMAD7 on drug resistance and apoptosis of MM cells were observed.

Results

·The analysis of SMAD7 expression data in the datasets showed that compared with healthy donors, SMAD7 expression in MM patients was higher (all P<0.05). The results of qPCR showed that the relative expression of SMAD7 mRNAwas up-regulated in MM patients (P=0.002), although no correlation with clinical information of patients was shown. Compared with the control cells, the cell viability of KMS11 was higher after overexpression of SMAD7 (all P<0.05); the change of cell cycle distribution showed that the proportion of cells in S phase decreased (P=0.016), and the proportion of cells in G2/M phase increased (P=0.005); after bortezomib treatment, the drug sensitivity and apoptosis level of overexpression SMAD7 cells was lower.

Conclusion

·The expression of SMAD7 is up-regulated in MM. Overexpression of SMAD7 can promote the proliferation and drug resistance of MM cells.

Key words： Sma- and Mad-related protein 7 (SMAD7); multiple myeloma (MM); cell proliferation; bortezomib

参考文献

1 KUMAR S K, RAJKUMAR V, KYLE R A, et al. Multiple myeloma[J]. Nat Rev Dis Primers, 2017, 3: 17046.
2 MINNIE S A, HILL G R. Immunotherapy of multiple myeloma[J]. J Clin Invest, 2020, 130(4): 1565-1575.
3 ROBAK P, DROZDZ I, SZEMRAJ J, et al. Drug resistance in multiple myeloma[J]. Cancer Treat Rev, 2018, 70: 199-208.
4 MIKKILINENI L, KOCHENDERFER J N. CAR T cell therapies for patients with multiple myeloma[J]. Nat Rev Clin Oncol, 2021, 18(2): 71-84.
5 SHAH U A, MAILANKODY S. Emerging immunotherapies in multiple myeloma[J]. BMJ, 2020, 370: m3176.
6 TORIMOTO Y, SHINDO M, IKUTA K, et al. Current therapeutic strategies for multiple myeloma[J]. Int J Clin Oncol, 2015, 20(3): 423-430.
7 ZHU M, ZHANG N, HE S X, et al. Exosomal miR-106a derived from gastric cancer promotes peritoneal metastasis via direct regulation of Smad7[J]. Cell Cycle, 2020, 19(10): 1200-1221.
8 LIU X, LEE J, COOLEY M, et al. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma[J]. Cancer Res, 2003, 63(22): 7760-7768.
9 ZHANG Z K, FAN Y, XIE F, et al. Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7[J]. Nat Commun, 2017, 8(1): 2116.
10 SEHRAWAT A, SHIOTA C, MOHAMED N, et al. SMAD7 enhances adult β-cell proliferation without significantly affecting β-cell function in mice[J]. J Biol Chem, 2020, 295(15): 4858-4869.
11 KLEEFF J, ISHIWATA T, MARUYAMA H, et al. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer[J]. Oncogene, 1999, 18(39): 5363-5372.
12 LI H, LI J, CHEN L, et al. HERC3-mediated SMAD7 ubiquitination degradation promotes autophagy-induced EMT and chemoresistance in glioblastoma[J]. Clin Cancer Res, 2019, 25(12): 3602-3616.
13 JIAO C, LI L, ZHANG P, et al. REGγ ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF-β pathway[J]. Cell Death Differ, 2020, 27(2): 497-508.
14 TONG L, SHEN S H, HUANG Q, et al. Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis[J]. Cell Death Differ, 2020, 27(6): 1795-1806.
15 ZHAO S L, SUN H C, JIANG W L, et al. miR-4775 promotes colorectal cancer invasion and metastasis via the Smad7/TGFβ-mediated epithelial to mesenchymal transition[J]. Mol Cancer, 2017, 16(1): 12.
16 BAUGHN L B, DI LIBERTO M, NIESVIZKY R, et al. CDK2 phosphorylation of Smad2 disrupts TGF-β transcriptional regulation in resistant primary bone marrow myeloma cells[J]. J Immunol, 2009, 182(4): 1810-1817.
17 YU Y, GU S C, LI W J, et al. Smad7 enables STAT3 activation and promotes pluripotency independent of TGF-β signaling[J]. Proc Natl Acad Sci USA, 2017, 114(38): 10113-10118.
18 ALAS S, BONAVIDA B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis[J]. Clin Cancer Res, 2003, 9(1): 316-326.
19 ZHU Y X, SHI C X, BRUINS L A, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4[J]. Blood Cancer J, 2019, 9(2): 19.
20 ISHIKAWA H, TSUYAMA N, LIU S Q, et al. Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals[J]. Oncogene, 2005, 24(41): 6328-6332.
Options
文章导航

/

〈 〉